Kombiglyze XR 5mg/1000mg Tablet is a fixed-dose combination medication containing Saxagliptin 5mg and Metformin 1000mg, indicated for the management of type 2 diabetes mellitus. Saxagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the incretin system by increasing levels of active incretin hormones, which in turn improve glucose-dependent insulin secretion and suppress glucagon release, thereby aiding in glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake. The extended-release formulation allows for once-daily dosing, improving patient compliance and maintaining stable plasma drug concentrations. Kombiglyze XR is typically prescribed when diet and exercise alone are insufficient to achieve adequate glycemic control or when monotherapy with either agent is inadequate. It is contraindicated in patients with severe renal impairment, metabolic acidosis, or known hypersensitivity to its components. Common adverse effects include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, which often diminish over time. Regular monitoring of renal function and glycemic parameters is recommended during therapy. This combination offers a complementary mechanism of action, providing effective and convenient glycemic management in patients with type 2 diabetes.